The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy
Open Access
- 9 July 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 114 (2) , 380-393
- https://doi.org/10.1182/blood-2008-10-182758
Abstract
LAQ824 and LBH589 (panobinostat) are histone deacetylase inhibitors (HDACi) developed as cancer therapeutics and we have used the Eμ-myc lymphoma modeKeywords
This publication has 57 references indexed in Scilit:
- The Roles of Therapy-Induced Autophagy and Necrosis in Cancer TreatmentClinical Cancer Research, 2007
- Role of autophagy in cancerNature Reviews Cancer, 2007
- The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug ResistanceCancer Research, 2006
- Is Apaf-1 expression frequently abrogated in melanoma?Cell Death & Differentiation, 2005
- Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cellsNature Medicine, 2004
- Epigenetics and cancerGenes & Development, 2004
- Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington diseaseNature Genetics, 2004
- Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia CellsCancer Research, 2004
- Methods for monitoring autophagyThe International Journal of Biochemistry & Cell Biology, 2004
- Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.2003